DCOY Decoy Therapeutics Inc.
Listings ·
Nasdaq said on December 31, 2025 that the company missed the $1.00 minimum bid price and gets no grace period. Suspension is set for January 9, 2026 unless it appeals by January 7, 2026.
Salarius said $2.4 million from an at-the-market program and $3.8 million from C/M Capital Master Fund, LP lifted its stockholders' equity above the $2.5 million Nasdaq minimum. The figure is preliminary, and Nasdaq has not yet confirmed compliance.
Salarius cut its relative valuation in the Decoy merger from $4.6 million to $2.31 million, so its legacy holders would keep 7.6% of the combined company instead of 14.1%. The 8-K blames "substantial deterioration" in its share price.
Nasdaq says the stock's bid price was below $1.00 for 30 consecutive business days and, after a recent reverse stock split, no compliance period applies. The company plans to appeal by April 30, 2025.
Salarius Pharmaceuticals agreed on December 12, 2024 to let C/M Capital Master Fund, LP purchase up to $10 million of its common stock over 36 months, once a resale registration is effective. The 8-K names no placement agent or counsel, and it gives the company's Nasdaq symbol as SLRX.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $368,170 | $770,027 |
| Net income (loss) | -$12.5 million | -$5.6 million |
| Cash from operations | -$4.8 million | -$4.5 million |
| Cash and equivalents | $10.7 million | $2.4 million |
Our latest story on this, dated Apr 25, 2025: "Salarius Pharmaceuticals (now Decoy Therapeutics) gets Nasdaq delisting notice, plans appeal". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jan 2, 2026: "Salarius Pharmaceuticals (now Decoy Therapeutics) gets Nasdaq delisting notice, will appeal". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Oct 6, 2025: "Salarius (now Decoy Therapeutics) says share sales lift equity above Nasdaq minimum". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jun 11, 2025: "Salarius (now Decoy Therapeutics) cuts its valuation to $2.31 million in merger deal". The story links the filing or release it is based on. Read the story.
Decoy Therapeutics Inc. trades under the ticker DCOY on NASDAQ.
Decoy Therapeutics Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Decoy Therapeutics Inc. is 1615219. Its filings are on SEC EDGAR.
655,185 shares as of 2026-08-12, per the cover page of its 10-Q filed 2026-08-12.
Our directory records Decoy Therapeutics Inc. under United States.
Our directory classifies Decoy Therapeutics Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Decoy Therapeutics Inc. is US79400X6022.
aibio.space lists Decoy Therapeutics Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Decoy Therapeutics Inc. reported a net loss of $12.5 million for the fiscal year ended Dec 31, 2025, and used $4.8 million of cash in operations, per its annual report to the SEC.
$368,170 in the fiscal year ended Dec 31, 2025, per its annual report.
Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,8.01,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 7.01). Source
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,3.02,3.03,5.02,5.03,8.01,9.01). Source
Set up an at-the-market program to sell shares over time. SEC Form 424B4. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,8.01,9.01). Source
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 1.01,3.03,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 1.01,3.01,9.01). Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,3.02,7.01,8.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio